Atriva Therapeutics
When prevention fails: host-targeting therapy for severe viral disease
The Atriva Approach
First-in-class host-targeting therapies
to treat infections caused for example by influenza viruses, respiratory
syncytial virus, dengue fever virus and hanta virus.
Great potential against a wide variety of respiratory viruses due to antiviral and immunomodulating activity of ATRIVA’s lead product zapnometinib (INN). Phase I successfully completed. RESPIRE trial (Phase II in COVID-19) finished with highly promising results. Phase II in influenza currently planned.
Atriva News
Stay informed on Atriva Therapeutics
MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection
Frontiers | MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection (frontiersin.org)
Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2
Frontiers | Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2 (frontiersin.org)
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
• Atriva Therapeutics and Canadian Biocure Technology, Inc. entered into an exclusiveletter agreement for a reverse takeover transaction.• Upon successful completion of …
17 – 20 September 2023 Atriva Therapeutics to present at 9th European Scientific Working Group on Influenza (ESWI) Conference in Valencia
Our non-clinical activities yielded promising results in influenza and SARS-CoV-2 cell line studies and animal studies. We're now planning the Phase 2 …
Atriva Therapeutics selected to present new study data at the <a href="https://eswiconference.org/"><strong>9th European Scientific Working Group on Influenza (ESWI)</strong></a> Conference in Valencia from 17-20 September 2023.
Our non-clinical activities yielded promising results in influenza and COVID-19 cell line studies and animal studies. We're now planning the Phase 2 …
Atriva Therapeutics appoints Christian Pangratz as Chief Executive Officer, implementing planned management change
Christian Pangratz to become Chief Executive Officer of Atriva Therapeutics GmbH effective January 15, 2023 Dr. Rainer Lichtenberger, co-founder and CEO, retires …
Atriva Therapeutics GmbH moves into the Innovation and Start-Up Center for Biotechnology (IZB)
The Innovation and Start-Up Center for Biotechnology (IZB), one of the leading biotechnology centers in Europe with over 50 biotech start-ups based …